Acodin Syrup

Quick links to important sections

Acodin Syrup

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acodin Syrup

Property Description
Active ingredient Dextromethorphan Hydrobromide (DM)
Form Oral Solution (Syrup), often flavored
Pharmacological class Antitussive (Cough Suppressant)
Common use Temporary relief of dry, irritating coughs
Origin Synthetic Compound

Acodin Syrup: Identity and General Therapeutic Use

Acodin Syrup is a clinically recognized oral antitussive medication typically distributed as an over-the-counter (OTC) liquid solution. It is used primarily for the temporary relief of a non-productive, or dry, irritating cough. Its therapeutic role is strictly symptomatic, focusing on managing the persistent urge to cough that is not associated with the expulsion of phlegm or mucus.

The medication is utilized to address the symptomatic discomfort of dry coughing. The formulation often features a pleasant flavor, which is a key differentiating factor aimed at improving acceptance, particularly in the pediatric patient group, though specific guidelines vary by country.

What is the Active Ingredient in Acodin Syrup?

The key active ingredient in Acodin Syrup is Dextromethorphan Hydrobromide (DM), a compound that belongs to the morphinan pharmacological class. As a synthetic compound, Dextromethorphan is chemically derived rather than being sourced from plants, which ensures consistent potency and quality across every batch.

Dextromethorphan's primary function is its antitussive property, which involves acting centrally on the cough reflex center in the brain. The drug is classified within the morphinan class, a categorization that signals its structural relationship to certain opioids, though it is specifically recognized for its potent cough-suppressing action without significant analgesic or addictive properties at therapeutic doses. Acodin Syrup is an oral preparation, designed for systemic absorption to facilitate this central action.

What side effects are possible with Acodin Syrup?

Possible Side Effects and Safety Information

The safety profile of Acodin Syrup, which contains dextromethorphan (DM), is based on government regulatory documentation and structured around potential adverse reactions and critical restrictions.

Frequency-Classified Adverse Reactions

The most frequently documented side effects generally affect the nervous system and gastrointestinal tract. Regulatory sources classify these as common:

  • Nervous System: Dizziness, Drowsiness, Sedation.
  • Gastrointestinal System: Nausea, Vomiting, Constipation.

Serious Adverse Reactions and Restrictions

Certain reactions and interactions are considered serious and require strict adherence to regulatory limitations:

  • Critical Drug Interaction (Serotonin Syndrome): The medicine is contraindicated for use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI), due to the risk of developing a potentially life-threatening condition called Serotonin Syndrome. Symptoms can include agitation, rapid heart rate, and confusion.
  • Severe Allergic Reactions: While rare, severe hypersensitivity reactions, including significant rash, hives, or swelling, are documented safety concerns.
  • Impaired Alertness: Due to the risk of drowsiness, a safety restriction is placed on activities requiring full mental alertness, such as driving or operating heavy machinery.

Population and Context-Specific Safety Notes

  • Pregnancy and Lactation: Regulatory documents generally classify dextromethorphan in a category indicating potential risks cannot be ruled out, and specifically advise avoiding products containing high levels of alcohol during these periods.
  • Dose-Related Patterns: Use of high or excessive doses is noted in regulatory contexts for its association with toxicity and increased risk of serious adverse reactions.

Overdose and Emergency Response

Officially documented overdose presentations of Dextromethorphan Hydrobromide (the active ingredient in Acodin Syrup) reflect effects primarily on the Central Nervous System (CNS) and the cardiovascular system. Manifestations range from moderate symptoms to severe, life-threatening outcomes. Documented presentations include CNS symptoms such as confusion, severe drowsiness, agitation, hallucinations, and unsteadiness (ataxia). Cardiovascular effects like rapid heartbeat (tachycardia) and changes in blood pressure are also officially noted.

Immediate medical attention is required for the treatment of severe toxicity. The most serious outcomes documented in regulatory sources include respiratory depression (slowed or no breathing, or apnea), seizures, and coma. There is also a recognized risk for Serotonin Syndrome, particularly when an overdose involves co-ingestion with other serotonergic agents.

In the event of suspected overdose, regulatory guidance mandates that immediate medical advice should be sought. Emergency services must be contacted immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management is categorized as symptomatic and supportive, and procedures may include activated charcoal or gastric lavage, monitoring of vital signs and ECG, and the administration of supportive treatments. While no specific antidote is known, Naloxone may be considered by medical professionals for managing severe respiratory depression.

Therapeutic Uses of Acodin Syrup

What Acodin Syrup Treats: Main Uses and Benefits

Acodin Syrup is relevant for easing symptoms associated with heightened symptoms of the cough, specifically the non-productive type. The medication is commonly used to temporarily relieve cough caused by conditions such as the common cold or flu.

Relief for Dry, Non-Productive Coughs

The syrup is relevant for managing symptom clusters that may become intense or disruptive, and may assist with the dry, irritating, and persistent cough that does not yield phlegm. This antitussive is used in areas where short-term symptom management is appropriate, particularly for acute respiratory tract infections, and is commonly used when symptoms intensify temporarily.

Quick Fact: Relief for Dry, Irritating Cough

The therapeutic benefit supports the patient by contributing to easing the overall symptom load, especially when the dry cough interferes with daily functioning, such as sleep and rest. By addressing the symptoms of the cough reflex, the medication may assist with maintaining functional stability and helps support rest. As patients often note, “It supports the patient during difficult episodes by easing the distress caused by the persistent urge to cough.” This application contributes to easing discomfort during symptomatic periods and may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility for Acodin Syrup (Dextromethorphan)

Official regulatory documents define strict criteria for who is eligible to use Acodin Syrup. The medication is primarily authorized for use in adults and adolescents (typically 12 years and older) who do not present with specific contraindications. Use in geriatric patients is generally permitted without dose modification.

Absolute Contraindications

Acodin Syrup is contraindicated for several populations, including those with known hypersensitivity to dextromethorphan or any of the product's components. Absolute prohibition is required for patients who are currently using or have used a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days, due to the serious risk of adverse reactions. The medicine must also be avoided by individuals at risk of respiratory failure or those with a cough associated with excessive phlegm or secretions.

Age and Condition Restrictions

Use in children under 4 or 6 years is generally not recommended by regulatory authorities, and efficacy is not established in the youngest pediatric group. Conditional use is required for patients with hepatic impairment (liver dysfunction) and those identified as poor CYP2D6 metabolizers. Furthermore, regulatory guidance states that use during pregnancy and breastfeeding is restricted and generally not recommended unless deemed necessary by a clinician.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation identifies specific medicinal products and substance categories that interact with Acodin Syrup (dextromethorphan), resulting in a need for caution or contraindication. The core of the interaction profile centers on two primary risks: an increased risk of serotonin syndrome and the risk of increased drug concentration.

Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs): Use is strictly contraindicated with MAOIs (e.g., iproniazid, moclobemide, selegiline) and for a period of 14 days after stopping MAOI treatment. This restriction is due to a high risk of developing serotonin syndrome, a potentially serious condition.

Clinically Significant Interactions

Interacting Product Category Example Medicines Interaction Constraint
CYP2D6 Inhibitors Fluoxetine, Paroxetine, Quinidine, Amiodarone Co-administration may increase dextromethorphan concentration, risking overdose symptoms.
Other Serotonergic Agents Certain antidepressants/antipsychotics Increased risk of serotonin syndrome symptoms, requiring close monitoring.
Alcohol (Ethanol) All alcoholic beverages Consumption is restricted as it enhances the inhibitory effect of dextromethorphan on the central nervous system.
Expectorant Medicines N/A Use in patients with existing lung disease and excessive mucus accumulation may lead to increased mucus buildup.

In specific populations, such as patients with kidney or liver failure, an adjustment to the dose or dosing interval is required when taking certain interacting antidepressant or antipsychotic medicines.

Mechanism of Action

Acodin Syrup's primary active component, dextromethorphan (DM), exerts its central effect by acting on the brainstem's cough reflex circuitry. The drug's mechanism of action involves interaction with specific neuroreceptors and ion channels.

Modulating the Central Cough Reflex (Sigma-1 Agonism)

The drug acts as an agonist at sigma-1 (sigma-1) receptors, a non-opioid intracellular protein located within the medullary cough center of the brainstem. The agonism of this receptor is linked to an elevated signal threshold required for the activation of the cough reflex circuit, resulting in the modulation of downstream signaling in the efferent neural arc.

Influencing Excitatory Neurotransmission (NMDA Receptor Antagonism)

Dextromethorphan and its active metabolite, dextrorphan, also function as non-competitive antagonists at N-methyl-D-aspartate (NMDA) receptors in the central nervous system. This interaction involves a direct reduction in the flow of positive ions through the receptor's channel, thereby modulating excitatory neurotransmission mediated by the glutamate pathway.

Dosage and Administration Information

Administration Scope

The administration of Acodin Syrup, which contains Dextromethorphan Hydrobromide, is subject to established guidelines.

Feature Official Instruction Summary (Label-Based)
Route of administration Oral use only; the syrup must be swallowed.
Dosing schedule (Adults) Immediate-Release: 10 mg to 20 mg every 4 hours or 30 mg every 6 to 8 hours. The total dose must not exceed 120 mg in a 24-hour period.
Timing in relation to meals The medication may be taken with or without food.
Preparation requirements The bottle for oral suspensions (extended-release forms) must be shaken well before the dose is measured.
Age-group rules Dosing for children is strictly age-banded and lower than the adult limit. Some guidelines advise against use in children under 12 years or mandate specific consultation for those under a certain age (e.g., under 4 or 6 years).
Missed-dose rules If a dose is missed, patients are typically instructed to take the next dose at the regularly scheduled time without doubling the dose.
Special procedural conditions The measured volume must be drawn using a medication-measuring device supplied with the product; a common household spoon is not an approved device for measurement.

Instruction Classifications (High-Level)

Classification Official Pattern
Administration method type Oral solution/suspension.
Frequency pattern As-needed (for symptom relief), adhering to fixed intervals of every 4 hours, every 6 to 8 hours, or every 12 hours (extended-release).
Use-context constraints The product is officially labeled for temporary relief only. The medication should not be used if the cough persists for more than 7 days.

Connection to the overall use protocol

The official instructions define the required parameters for administering the solution, establishing that the correct dose must be measured precisely and taken via the oral route at labeled intervals. The protocol ensures that the usage is constrained by both a maximum daily dose (120 mg) and a maximum duration (e.g., 7 days), structuring its use as a short-term, symptomatic measure.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Research Focus and Dose-Finding

Early-stage research explored the basic activity and tolerability profile of the investigational drug.

  • Exploratory Focus: Early research explored a novel receptor pathway. Research protocols were designed to measure initial indicators of drug response.
  • Dose Exploration: Initial studies examined various dosages to assess tolerability and identify a dose range for further investigation.

Phase III Trials: Efficacy and Safety Research

Large-scale trials further examined the potential effects and safety profile of the investigational drug in a diverse participant population.

Core Efficacy Research

  • Joint Mobility: The pivotal studies evaluated whether joint mobility was affected in participants over a 52-week period. Primary endpoints focused on objective measures of joint function.
  • Symptom Changes: Studies evaluated the time-course of changes in acute symptoms, comparing the investigational drug group to a placebo group.
  • Disease Activity: The primary Phase III trial reported changes in disease activity over the study period. Secondary analysis explored these changes relative to patient-reported outcomes (PROs).

Combination Use Research

Studies examined outcomes when used in combination, compared to the current standard of care. This research focused on whether the combined approach altered the reported incidence of side effects.

  • Interactions: Research has explored drug-drug interactions when used with other pain medications.
  • Outcomes: The trial evaluated pain scores in the combination group over a six-month period.

Subgroup Analysis

Research has explored the drug's activity in participants with severe disease. Subgroup analyses included data from older adult participants and those with varying disease duration.

  • Liver Function: Studies included an examination of changes in liver function in participants with mild liver impairment.
  • Patient History: Research protocols noted the assessment of participant medical history prior to enrollment.

Safety and Tolerability Summary

  • Adverse Events: The most frequently reported adverse events included mild nausea and headache, with event resolution documented during the first month of the study.
  • Serious Side Effects: The incidence of serious side effects reported in the trials was documented.

Key Studies & References

  1. Dextromethorphan Pediatric Acute Cough Study (CHPA DXM) - ClinicalTrials.gov
  2. Dextromethorphan Pre-Review Report - World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD 2012)
  3. Dextromethorphan - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Acodin Syrup (FAQ)


Q: How quickly can I expect Acodin Syrup to start working?

According to official documentation, the active ingredient, dextromethorphan, is typically absorbed from the stomach and intestines after swallowing the syrup. It begins to exert its effect once sufficient amounts reach the brain's cough center.


Q: Is Acodin Syrup known to cause drowsiness?

Yes, official regulatory documents list mild drowsiness and fatigue as documented adverse effects that may occur, even when the product is used at the recommended therapeutic doses. This potential effect is noted in official information.


Q: Do any official sources mention how long the effects of Acodin Syrup are supposed to last?

The official dosing instructions, such as taking the medicine every 4 or every 6 to 8 hours, reflect the intended duration of the drug’s effects in the body. The half-life, which describes the time it takes for half of the drug to be processed, is generally reported to be between 1.2 to 3.9 hours.


Q: Are there research studies looking into the long-term use of Acodin Syrup?

Dextromethorphan-containing products are officially labeled for the temporary relief of cough symptoms. Official product information notes that the product is labeled for temporary use and that usage should not exceed a specific short-term period, such as 7 days.


Q: What are the official restrictions for people with liver conditions using Acodin Syrup?

Official monographs advise caution for individuals with hepatic impairment, which refers to impaired liver function. This caution is noted because the drug's metabolism can be affected by the condition.


Q: Are there any known interactions between Acodin Syrup and antidepressant medications?

Official sources state that use with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated. Additionally, combining the drug with other serotonergic agents, which include certain antidepressants, is noted to increase the risk of a serious condition called serotonin syndrome.


Q: Can the main ingredient in Acodin Syrup affect blood pressure?

At standard therapeutic doses, the main ingredient does not typically cause classical changes in blood pressure. However, in cases of serious adverse reactions or accidental overdose, effects such as rapid heart rate (tachycardia) and elevated blood pressure (hypertension) have been noted.


Q: What are the potential effects of accidentally taking more Acodin Syrup than advised?

Regulatory information indicates that the use of excessive doses is associated with toxicity. Potential effects include confusion, nervousness, agitation, severe nausea and vomiting, and an increased risk of serious side effects like breathing difficulties.


Q: What official information is available about Acodin Syrup and kidney function?

Official monographs typically note that caution is advised for patients with severe kidney dysfunction. This is because the condition may impact the drug's clearance from the body, potentially affecting concentration levels.


Q: Does the syrup form less potent than the tablet form of Acodin?

The drug's potency is standardized by the amount of active ingredient, Dextromethorphan Hydrobromide, measured in milligrams. Both liquid and tablet forms are manufactured to deliver the same dosage strength in milligrams, though their absorption profiles in the body may vary.


Q: What is the difference between Acodin Syrup and cough drops?

Acodin Syrup contains Dextromethorphan, which is classified as an antitussive medicine that works centrally by suppressing the cough reflex in the brain. Cough drops generally contain ingredients, such as local anesthetics or demulcents, that act locally in the throat to soothe irritation.


Q: Why do some people say Acodin Syrup makes them feel 'off' or unusual?

The product's profile of common side effects includes effects on the central nervous system, such as dizziness, mild drowsiness, and sedation. These effects, as listed in official documentation, may contribute to a feeling of being unusual or 'off.'


Q: Is it normal to feel a dry mouth after taking Acodin Syrup?

While dry mouth is not always listed as a common side effect for dextromethorphan specifically, it is a recognized potential effect associated with the overall class of antitussive medicines. If experienced, this effect is usually mild.


Q: Does Acodin Syrup interact with caffeine or energy drinks?

Warnings in official documents emphasize interactions with central nervous system depressants like alcohol. While not a formal contraindication, combining the product with stimulants such as caffeine may raise the risk of side effects like nervousness or increased heart rate.


Q: Can Acodin Syrup affect sleep patterns?

The medicine is associated with adverse reactions like drowsiness and sedation, which can affect the natural sleep cycle. Furthermore, some clinical studies have reported insomnia, or difficulty sleeping, more frequently in participants taking the active ingredient.


Q: How does the concentration of the active ingredient in Acodin Syrup compare to a tablet form?

The drug’s concentration is typically measured in milligrams per milliliter (mg/mL) for the syrup, while the tablet is measured in total milligrams (mg). Manufacturers provide guidelines to ensure the prescribed volume of syrup delivers an equivalent total dose in milligrams to the tablet.


Q: What does the research say about the effectiveness of Acodin Syrup in children?

Regulatory bodies generally indicate that use of these medicines is not recommended in children under 6 years of age. The effectiveness in this population has been noted as not robustly established, which impacts the risk-benefit assessment in the youngest age groups.

How should Acodin Syrup be stored and disposed of?

How to Store and Dispose of Acodin Syrup?

The storage and disposal of Acodin Syrup (Dextromethorphan Hydrobromide) must follow specific regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Condition Regulatory Mandate
Temperature Store at a temperature not exceeding 25 C (77 F).
Protection The medicine must be protected from light and protected from freezing.
Container Store in the original container and keep the container tightly closed.
Child Safety Keep out of the sight and reach of children (container often features a child-resistant cap).

Disposal Instructions

Expired or unused Acodin Syrup must not be disposed of in household waste or wastewater. The product and container must be disposed of at an approved waste disposal plant, following all applicable local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acodin Syrup found in:

A-Z Index: